Loew D
Wien Med Wochenschr. 2002;152(15-16):418-22. doi: 10.1046/j.1563-258x.2002.02065.x.
During the last decade, there has been an explosive growth of research concerning the extract of Ginkgo biloba termed Egb 761. In experimental studies, animal studies and clinical studies Ginkgo biloba has shown a similar pharmacological potency and clinical efficacy like synthetic defined drugs in the therapy of reduced cerebral performance. Ginkgo biloba special extract Egb 761 is a standardized and highly purified extract of Ginkgo leaves. Among the active constituents are the ginkgo-flavone glycosides and the terpene-lactones (ginkgolides, bilobalide). The multifactorial principle of action of Ginkgo biloba is characterized by rheological and blood-flow-promoting properties, protective effects against ischaemia and hypoxia, effects on nerve cell energy metabolism, antioedematous and myelin-protective effects, radical-scavenger activity, effects on various cerebral transmitter and receptor systems. These action principles constitute the rationale for clinical trials in vascular dementia and primary degenerative dementia of the Alzheimer type, and in mixed forms of both. The cerebral bioavailability of Ginkgo biloba extract has been demonstrated by electroencephalography. In clinical trials of different working-groups, effects of Ginkgo biloba on the cognitive performance, global function, and activities of the daily living have been found. Metaanalysis in the indication--demential disorders--comparing Ginkgo biloba versus acetylcholinesterase inhibitors have shown a similar clinical efficacy of both therapy regimens with an additional drug safety benefit for Ginkgo. Due to the clinical efficacy the WHO accepted Ginkgo biloba as an antidementiv drug and add it in January 2000 into the recent ATC-Classification Index. In future antidementive therapy drugs with an different mode of action should be given in combination. Furthermore clinical trials with fixed combinations of acetylcholinesterase inhibitors with Ginkgo biloba extracts in moderate or severe dementia would be necessary.
在过去十年中,关于银杏叶提取物Egb 761的研究呈爆发式增长。在实验研究、动物研究和临床研究中,银杏叶在治疗脑功能减退方面显示出与合成的特定药物相似的药理效力和临床疗效。银杏叶特殊提取物Egb 761是一种标准化且高度纯化的银杏叶提取物。其活性成分包括银杏黄酮苷和萜类内酯(银杏内酯、白果内酯)。银杏叶的多因素作用原理表现为流变学和促进血流的特性、对缺血和缺氧的保护作用、对神经细胞能量代谢的影响、抗水肿和保护髓鞘的作用、自由基清除活性、对各种脑递质和受体系统的影响。这些作用原理构成了针对血管性痴呆、阿尔茨海默型原发性退行性痴呆以及两者混合形式进行临床试验的理论依据。银杏叶提取物的脑生物利用度已通过脑电图得到证实。在不同研究团队的临床试验中,发现了银杏叶对认知能力、整体功能和日常生活活动的影响。在痴呆症这一适应症方面进行的荟萃分析——比较银杏叶与乙酰胆碱酯酶抑制剂——显示两种治疗方案具有相似的临床疗效,且银杏叶具有额外的药物安全性优势。由于其临床疗效,世界卫生组织将银杏叶认可为一种抗痴呆药物,并于2000年1月将其纳入最新的ATC分类索引。在未来的抗痴呆治疗中,应联合使用作用方式不同的药物。此外,对于中度或重度痴呆患者,有必要开展乙酰胆碱酯酶抑制剂与银杏叶提取物固定组合的临床试验。